BACKGROUND: Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. OBJECTIVES: The primary objective is to evaluate HSR incidence in titrated first-dose rituximab infusions when priming IV lines with rituximab, as compared to priming with diluent. METHODS: A retrospective, comparative, descriptive study with two arms (rituximab- versus diluent-primed) was conducted. Variables were HSR incidence in relation to priming method, age, sex, diagnosis, and premedications. For patients with HSR, severity, time to onset, and infusion rate were examined. FINDINGS: HSR incidence was significantly higher in the diluent- versus the drug-primed arm. Other significant findings included higher HSR incidence in women and lower HSR incidence in patients premedicated with dexamethasone.
BACKGROUND: Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. OBJECTIVES: The primary objective is to evaluate HSR incidence in titrated first-dose rituximab infusions when priming IV lines with rituximab, as compared to priming with diluent. METHODS: A retrospective, comparative, descriptive study with two arms (rituximab- versus diluent-primed) was conducted. Variables were HSR incidence in relation to priming method, age, sex, diagnosis, and premedications. For patients with HSR, severity, time to onset, and infusion rate were examined. FINDINGS: HSR incidence was significantly higher in the diluent- versus the drug-primed arm. Other significant findings included higher HSR incidence in women and lower HSR incidence in patients premedicated with dexamethasone.
Entities:
Keywords:
IV lines; cytokine release syndrome; hypersensitivity reaction; priming; rituximab
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: L D Piro; C A White; A J Grillo-López; N Janakiraman; A Saven; T M Beck; C Varns; S Shuey; M Czuczman; J W Lynch; J E Kolitz; V Jain Journal: Ann Oncol Date: 1999-06 Impact factor: 32.976
Authors: Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith Journal: Blood Date: 2004-10-19 Impact factor: 22.113
Authors: Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544